Skip to main content

Table 1 Basal and operative characteristics of patients enrolled into the study

From: Impact of epicardial ablation of concomitant atrial fibrillation on atrial natriuretic peptide levels and atrial function in 6 months follow-up: does preoperative ANP level predict outcome of ablation?

 

AF ablation group (n = 42)

AF control group without ablation (n = 16)

SR control group (n = 20)

p-value

Demography

    

  Age [years]

71.3 ± 8.3

73.8 ± 6.6

68.9 ± 7.0

0.16

  Male gender, n (%)

31 (73,8%)

12 (75%)

15 (75%)

0.99

  Body Mass Index (kg/m2)

29.4 (5.3)

27.5 (4.9)

29.2 (3.9)

0.38

AF duration [months]

64.8 ± 57.1

73.0 ± 92.9

0

0.291

Type of AF %, (n)

    

HRS/AHA (ACC:

initial

reclassified

initial

reclassified

  

  1. Paroxysmal

11.9%

11.9% (5)

25.0%

25.0% (4)

0

 

  2. Persistent

23.8%

23.8% (10)

31.2%

31.2% (5)

0

 

  3. Longstanding pers.

21.4%

64.3% (27)

12.5%

43.7% (7)

0

 

  4. Permanent

42.9%

------

31.2%

------

0

 

Cox - classification:

    

  Intermittent

35.7% (15)

56.2% (9)

0

0.231

  Continuous

64.3% (27)

43.7% (7)

0

0.231

Preop. cardioversion (DC), n (%)

11 (26.2%)

5 (31.2%)

1 (5%)

 

Preop. catheter ablation, n (%)

2 (4.8%)

0

0

 

Preop. perm. anticoagulation, n (%)

26 (61.9%)

9 (56.2%)

1 (5%)

 

Previous cardiac surgery

0

3 (18.75%)

0

 

Comorbidity, n (%)

    

Stroke

6 (14.3%)

2 (12.5%)

1 (5%)

 

Heart failure (CHF)

25 (59.5%)

10 (62.5%)

7 (35%)

 

Myocardial infarction

12 (28.6%)

5 (31.3%)

7 (35%)

 

Pre-op. creatinine [mg/dl]

1.3 ± 0.32

1.29 ± 0.35

1.09 ± 0.28

0.13

ECHO data

    

  EF (Simpson) [%]

54.1 ± 10.8

54.1 ± 14.4

61.0 ± 9.0

0.07

  Max. LA area [cm2]

27.7 (24.1-32.4)

27.8 (23.5-30.4)

20.3 (14.7-24.6)

0.651 , p < 0.001 2

  Max. LA diameter (LAD) [mm]

48.5 ± 7.0

47.5 ± 7.2

41.7 ± 6.5

0.651 , p < 0.01 2

  LA AFF [%]

0 (0–25.2)

0 (0–34.9)

43.2 (32.4-52.8)

p > 0.051 , p < 0.001 2

Procedures

    

Without mitral-surg., n (%)

32 (76%)

12 (75%)

18 (90%)

1.01,20.372

  CABG

12 (28.6%)

2 (12.5%)

13 (65%)

 

  AVR

7 (16.7%)

3 (18.75%)

5 (25%)

 

  Aortic replacement

1 (2.3%)

-

-

 

  AVR + CABG

11 (26.2%)

3 (18.75%)

-

 

  AVR + Aortic replacement

-

2 (12.5%)

  

  Aortic replacement + CABG

1 (2.3%)

 

-

 

  Tricuspid valve surgery

-

1 (6.25%)

-

 

  VSD

-

1 (6.25%)

-

 

With mitral-surgery, n (%)

10 (23.8%)

4 (25%)

2 (10%)

1.01, 0.372

Euroscore II (%)

3.0 ± 2.36

4.3 ± 3.15

1.94 ± 1.54

0.007 2

LAA Amputation, n (%)

9 (21.4%)

2 (12.5%)

1 (5%)

 

RAA Amputation, n (%)

42 (100%)

16 (100%)

20 (100%)

 
  1. Abbreviations comment: AF atrial fibrillation, SR sinus rhythm, LA left atrium, AFF atrial filling fraction, AVR aortic valve replacement, VSD ventricular septal defect, MV mitral valve, MVR mitral valve replacement, LAA left atrial appendage, RAA right atrial appendage; 1represents the differences between AF ablation group and AF control group without ablation; 2represents the differences between AF ablation group vs SR control group and AF control group without ablation vs SR control group. Values are demonstrated as mean ± SD or median (25–75 percentiles).
Back to article page

Journal of Cardiothoracic Surgery

ISSN: 1749-8090

Contact us